PUT/VERTEX PHARMACEUTICALS/500/0.1/17.01.25 | Real-time BOERSE MUENCHEN 03:03:10 2024-07-17 am EDT | ||
| 3.34 EUR | +3.41% |
|
| Current month | -20.83% | ||
| 1 month | -16.32% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 3.34 | +3.41% |
| 24-07-16 | 3.23 | +5.21% |
| 24-07-15 | 3.07 | -4.36% |
| 24-07-12 | 3.21 | +0.63% |
| 24-07-11 | 3.19 | -1.24% |
Real-time BOERSE MUENCHEN
Last update July 17, 2024 at 03:03 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG1XE8 |
| ISIN | DE000GG1XE88 |
| Date issued | 2024-01-05 |
| Strike | 500 $ |
| Maturity | 2025-01-17 (185 Days) |
| Parity | 10 : 1 |
| Emission price | 8.04 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.25 € |
|---|---|
| Lowest since issue | 3.02 € |
| Spread | 0.13 € |
| Spread % | 3.75% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
489
USD
Average target price
473.5
USD
Spread / Average Target
-3.17%
- Stock Market
- Warrants
- Warrant
